InChI=1S/C97H144FN33O19S2/c98- 60- 33- 31- 58(32- 34- 60) 78(135) 119- 65(19- 8- 42- 113- 93(104) 105) 79(136) 121- 68(21- 10- 44- 115- 95(108) 109) 83(140) 126- 73(51- 56- 25- 30- 57- 14- 1- 2- 15- 59(57) 48- 56) 87(144) 130- 75- 53- 152- 151- 52- 74(88(145) 118- 63(77(101) 134) 18- 7- 41- 112- 92(102) 103) 129- 84(141) 69(23- 12- 46- 117- 97(111) 150) 122- 81(138) 66(20- 9- 43- 114- 94(106) 107) 124- 86(143) 72(50- 55- 28- 37- 62(133) 38- 29- 55) 128- 90(147) 76- 24- 13- 47- 131(76) 91(148) 70(17- 4- 6- 40- 100) 125- 82(139) 64(16- 3- 5- 39- 99) 120- 80(137) 67(22- 11- 45- 116- 96(110) 149) 123- 85(142) 71(127- 89(75) 146) 49- 54- 26- 35- 61(132) 36- 27- 54/h1- 2,14- 15,25- 38,48,63- 76,132- 133H,3- 13,16- 24,39- 47,49- 53,99- 100H2,(H2,101,134) (H,118,145) (H,119,135) (H,120,137) (H,121,136) (H,122,138) (H,123,142) (H,124,143) (H,125,139) (H,126,140) (H,127,146) (H,128,147) (H,129,141) (H,130,144) (H4,102,103,112) (H4,104,105,113) (H4,106,107,114) (H4,108,109,115) (H3,110,116,149) (H3,111,117,150) /t63- ,64- ,65- ,66- ,67- ,68- ,69- ,70+,71- ,72- ,73- ,74- ,75- ,76- /m0/s1 |
JJVZSYKFCOBILL-KZGZZEQFSA-N |
[H] [C@@] 12CCCN1C(=O) [C@@H] (CCCCN) NC(=O) [C@H] (CCCCN) NC(=O) [C@H] (CCCNC(N) =O) NC(=O) [C@H] (CC1=CC=C(O) C=C1) NC(=O) [C@H] (CSSC[C@H] (NC(=O) [C@H] (CCCNC(N) =O) NC(=O) [C@H] (CCCNC(N) =N) NC(=O) [C@H] (CC1=CC=C(O) C=C1) NC2=O) C(=O) N[C@@H] (CCCNC(N) =N) C(N) =O) NC(=O) [C@H] (CC1=CC2=C(C=CC=C2) C=C1) NC(=O) [C@H] (CCCNC(N) =N) NC(=O) [C@H] (CCCNC(N) =N) NC(=O) C1=CC=C(F) C=C1 |
|
Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
|
|
apoptosis inducer
Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
C-X-C chemokine receptor type 4 antagonist
An antogonist that blocks C-X-C chemokine receptor type 4 (CXCR-4).
|
|
antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
|
|
View more via ChEBI Ontology
(3S,6S,9S,12R,17R,20S,23S,26S,29R,34aS)- 26,29- bis(4- aminobutyl)- N- [(2S)- 1- amino- 5- carbamimidamido- 1- oxopentan- 2- yl]- 17- {[(2S)- 2- {[(2S)- 5- carbamimidamido- 2- {[(2S)- 5- carbamimidamido- 2- (4- fluorobenzamido)pentanoyl]amino}pentanoyl]amino}- 3- (naphthalen- 2- yl)propanoyl]amino}- 6- (3- carbamimidamidopropyl)- 9,23- bis[3- (carbamoylamino)propyl]- 3,20- bis(4- hydroxybenzyl)- 1,4,7,10,18,21,24,27,30- nonaoxotriacontahydro- 1H,16H- pyrrolo[2,1- p][1,2,5,8,11,14,17,20,23,26,29]dithianonaazacyclodotriacontine- 12- carboxamide (non- preferred name)
|
motixafortida
|
WHO MedNet
|
motixafortide
|
WHO MedNet
|
motixafortide
|
WHO MedNet
|
motixafortidum
|
WHO MedNet
|
4F-benzoyl-TN14003
|
ChemIDplus
|
BKT 140
|
ChemIDplus
|
BKT-140
|
ChEBI
|
BKT140
|
ChEBI
|
BL 8040
|
ChEBI
|
BL-8040
|
ChemIDplus
|
BL8040
|
ChEBI
|
TF 14016
|
ChemIDplus
|
TF-14016
|
ChEBI
|
TF14016
|
ChEBI
|
TN-14003
|
ChEBI
|
664334-36-5
|
CAS Registry Number
|
ChemIDplus
|
12935890
|
PubMed citation
|
Europe PMC
|
15207725
|
PubMed citation
|
Europe PMC
|
17525235
|
PubMed citation
|
Europe PMC
|
19322207
|
PubMed citation
|
Europe PMC
|
19584281
|
PubMed citation
|
Europe PMC
|
21138752
|
PubMed citation
|
Europe PMC
|
22925564
|
PubMed citation
|
Europe PMC
|
22992418
|
PubMed citation
|
Europe PMC
|
23489074
|
PubMed citation
|
Europe PMC
|
23637121
|
PubMed citation
|
Europe PMC
|
23906028
|
PubMed citation
|
Europe PMC
|
24246358
|
PubMed citation
|
Europe PMC
|
24502926
|
PubMed citation
|
Europe PMC
|
28280274
|
PubMed citation
|
Europe PMC
|
28835380
|
PubMed citation
|
Europe PMC
|
32451495
|
PubMed citation
|
Europe PMC
|
33270904
|
PubMed citation
|
Europe PMC
|
36901829
|
PubMed citation
|
Europe PMC
|
37069359
|
PubMed citation
|
Europe PMC
|
37996648
|
PubMed citation
|
Europe PMC
|
|